Linklaters advised Innate Pharma, a biotech company listed on Euronext Paris, on a capital increase reserved to institutional investors specialised in biotech and pharmaceutical sectors realised on 23 June 2014.

The private placement was entirely placed with leading international investors for an amount of 50 million Euro. The settlement-delivery of the new shares took place on 26 June 2014.

An application was made for admission of the new shares to trading on Euronext Paris, and a listing prospectus in connexion with the transaction was approved by the French financial markets authority on 24 June 2014.

The transaction was conducted by the Paris Capital Markets team composed of Bertrand Sénéchal, partner and Marie Gautier. Cyril Boussion advised on French Tax law issues.